Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the transaction, the executive vice president now directly owns 137,488 shares in the company, valued at approximately $10,174,112. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.87% during mid-day trading on Tuesday, reaching $73.74. 9,060,898 shares of the company’s stock traded hands. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $84.15. The company has a market capitalization of $96.36 billion, a price-to-earnings ratio of 7.79 and a beta of 1.20. The company has a 50-day moving average of $68.84 and a 200-day moving average of $68.56.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.18 by $0.02. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. Equities research analysts expect that Gilead Sciences, Inc. will post $8.42 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Investors of record on Friday, June 16th were given a $0.52 dividend. The ex-dividend date of this dividend was Wednesday, June 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is presently 21.99%.

TRADEMARK VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/07/25/gilead-sciences-inc-gild-evp-gregg-h-alton-sells-40000-shares.html.

A number of equities analysts recently issued reports on the company. Robert W. Baird reissued an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Tuesday. Leerink Swann reissued a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a report on Tuesday. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday. BMO Capital Markets reissued a “hold” rating and set a $72.00 price target on shares of Gilead Sciences in a report on Friday. Finally, Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Fifteen investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $80.09.

Several large investors have recently modified their holdings of GILD. Hall Laurie J Trustee increased its stake in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the period. Cable Hill Partners LLC increased its stake in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the period. Dubuque Bank & Trust Co. increased its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the period. Finally, Penserra Capital Management LLC increased its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the period. Institutional investors and hedge funds own 74.05% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.